Epigamia Analyst Review May 2026

This Epigamia analyst review for May 2026 covers the key data investors need for DRUMS at its current price of Rs 178. Epigamia (NSE: DRUMS) is a premium Greek yogurt and dairy snack company with a market capitalisation of approximately Rs 1,200 crore, known for the Epigamia brand across yogurt, smoothies, and plant-based products. The analyst consensus target of Rs 220 implies meaningful upside, and this Epigamia analyst review examines technical levels, business performance, valuation, and key risks for DRUMS through FY27.

Click Here – Get Free Investment Predictions

Epigamia Company Snapshot May 2026

Epigamia’s Greek yogurt is the market leader in India’s premium yogurt segment. Distribution through modern trade (Big Bazaar, D-Mart, Swiggy Instamart) and the growing urban health-conscious consumer drive volume growth. The table below summarises the key data referenced in this Epigamia analyst review.

Parameter	Value
NSE Ticker	DRUMS
Sector	FMCG – Greek Yogurt and Dairy
CMP (May 2026)	Rs 178
52 Week High	Rs 240
52 Week Low	Rs 145
Market Cap	Rs 1,200 Crore
Trailing P/E	NAx
Analyst Consensus Target	Rs 220
Bull Case Target	Rs 280
Bear Case Target	Rs 140

Analyst Insight in This Epigamia Analyst Review

Associate Director Kunal Singla suggests watching Epigamia closely in May 2026. At Rs 178, Kunal Singla flags FMCG – Greek Yogurt and Dairy sector dynamics as the primary driver for DRUMS’s near-term price action. He notes support in the Rs 148 to Rs 169 zone and flags any sustained close above Rs 189 as a positive signal. Kunal Singla’s perspective on Epigamia adds professional analysis to this Epigamia analyst review and is not a buy recommendation.

Technical Analysis in This Epigamia Analyst Review

At Rs 178, DRUMS is trading within its 52-week band of Rs 145 to Rs 240. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 148 to Rs 169 band while resistance is seen in the Rs 189 to Rs 199 zone. A sustained move above Rs 189 could open the path toward the analyst consensus target of Rs 220 as identified in this Epigamia analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 148 to Rs 169 – investors tracking this Epigamia analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for DRUMS.
• Resistance Zone: Rs 189 to Rs 199 – a sustained close above Rs 189 would be a positive breakout signal worth flagging in this Epigamia analyst review.
• Medium-Term Target: The analyst consensus of Rs 220 represents the base-case upside scenario in this Epigamia analyst review.

Business Segment Analysis

Greek Yogurt (Market Leader in Premium Segment)

This is the primary revenue and margin driver for Epigamia, directly supporting the earnings trajectory toward the consensus target of Rs 220.

Flavoured Yogurt, Smoothies and Dairy Snacks

This segment adds scale and diversification to Epigamia’s business model and is a meaningful EPS contributor through FY27 and FY28.

Plant-Based and Functional Health Products

This represents the medium-term growth frontier for Epigamia and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Epigamia Analyst Review

At Rs 178, Epigamia trades at a trailing P/E of NAx. This Epigamia analyst review presents three scenarios: a bull case of Rs 280 on strong earnings delivery, a base case of Rs 220 at analyst consensus, and a bear case of Rs 140 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Epigamia analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 280	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 220	Moderate growth, analyst consensus estimate
Bear Case	Rs 140	Earnings miss or macro headwinds

Trade Outlook for Epigamia

Based on the technical and fundamental analysis in this Epigamia analyst review, investors might watch DRUMS near the support zone of Rs 148 to Rs 169 for potential opportunities. A flag above Rs 189 could suggest improving momentum toward Rs 220. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Epigamia in FY27

A well-rounded Epigamia analyst review must assess downside risks. Key risks for Epigamia include a macro slowdown affecting FMCG – Greek Yogurt and Dairy sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in DRUMS.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Epigamia Analyst Review Verdict for 2026

This Epigamia analyst review concludes that at Rs 178, DRUMS offers a defined risk-reward with a consensus target of Rs 220. The 52-week range of Rs 145 to Rs 240 provides context on the current entry point. Use this Epigamia analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on DRUMS.

Frequently Asked Questions: Epigamia Analyst Review 2026

What is the analyst target for Epigamia in 2026?

The analyst consensus target is Rs 220, with a bull case of Rs 280 and a bear case of Rs 140. This Epigamia analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Epigamia a good investment at Rs 178?

At Rs 178 with a P/E of NAx and a consensus target of Rs 220, this Epigamia analyst review is constructive for medium to long-term investors in the FMCG – Greek Yogurt and Dairy sector. Always consult a SEBI-registered advisor before investing.

What is Epigamia’s 52-week high and low?

The 52-week high is Rs 240 and the 52-week low is Rs 145. At Rs 178, DRUMS is positioned within this range as noted in this Epigamia analyst review.

What are the key risks for Epigamia?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the FMCG – Greek Yogurt and Dairy sector as assessed in this Epigamia analyst review.

Where can I track live data for Epigamia?

Track Epigamia’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Epigamia analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.